SG Americas Securities LLC Grows Position in Fate Therapeutics, Inc. (NASDAQ:FATE)

SG Americas Securities LLC increased its position in Fate Therapeutics, Inc. (NASDAQ:FATE) by 30.6% in the fourth quarter, HoldingsChannel reports. The firm owned 44,874 shares of the biopharmaceutical company’s stock after purchasing an additional 10,511 shares during the quarter. SG Americas Securities LLC’s holdings in Fate Therapeutics were worth $74,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its position in Fate Therapeutics by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 2,258,246 shares of the biopharmaceutical company’s stock valued at $7,905,000 after buying an additional 10,863 shares in the last quarter. JPMorgan Chase & Co. increased its position in Fate Therapeutics by 18.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,837,304 shares of the biopharmaceutical company’s stock valued at $6,431,000 after buying an additional 283,080 shares in the last quarter. Barclays PLC increased its position in Fate Therapeutics by 245.3% during the 3rd quarter. Barclays PLC now owns 424,277 shares of the biopharmaceutical company’s stock valued at $1,485,000 after buying an additional 301,389 shares in the last quarter. FMR LLC increased its position in Fate Therapeutics by 25.9% during the 3rd quarter. FMR LLC now owns 227,981 shares of the biopharmaceutical company’s stock valued at $798,000 after buying an additional 46,892 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its position in Fate Therapeutics by 1,307.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 174,148 shares of the biopharmaceutical company’s stock valued at $610,000 after buying an additional 161,776 shares in the last quarter. Institutional investors own 97.54% of the company’s stock.

Analyst Upgrades and Downgrades

FATE has been the subject of a number of analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Fate Therapeutics in a research report on Tuesday, November 19th. Bank of America raised Fate Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Monday, November 18th. Finally, Wedbush reaffirmed a “neutral” rating and set a $5.00 price objective on shares of Fate Therapeutics in a research report on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $6.75.

Fate Therapeutics Price Performance

Shares of FATE opened at $1.27 on Friday. Fate Therapeutics, Inc. has a one year low of $1.04 and a one year high of $8.83. The firm has a market capitalization of $144.64 million, a P/E ratio of -0.77 and a beta of 2.02. The business has a fifty day moving average of $1.58 and a 200 day moving average of $2.69.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.02. The company had revenue of $3.07 million during the quarter, compared to analyst estimates of $0.88 million. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. Analysts expect that Fate Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.

Insider Activity at Fate Therapeutics

In related news, Director Redmile Group, Llc bought 397,964 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were bought at an average cost of $1.68 per share, for a total transaction of $668,579.52. Following the completion of the transaction, the director now owns 12,884,277 shares of the company’s stock, valued at approximately $21,645,585.36. This trade represents a 3.19 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.00% of the stock is owned by company insiders.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.